Kymera Therapeutics, Inc.
KYMR · NASDAQ
12/31/2024 | 12/31/2023 | 12/31/2022 | 12/31/2021 | |
|---|---|---|---|---|
| Valuation | ||||
| PEG Ratio | -0.74 | 0.95 | -0.23 | -0.29 |
| FCF Yield | -6.87% | -9.24% | -11.58% | -4.28% |
| EV / EBITDA | -13.81 | -10.20 | -8.54 | -30.90 |
| Quality | ||||
| ROIC | -28.33% | -33.35% | -28.87% | -19.20% |
| Gross Margin | 100.00% | 100.00% | 93.64% | 96.71% |
| Cash Conversion Ratio | 0.87 | 0.70 | 0.99 | 1.29 |
| Growth | ||||
| Revenue 3-Year CAGR | 0.17% | 2.57% | 11.22% | 191.71% |
| Free Cash Flow Growth | -51.01% | 11.94% | -19.44% | -265.17% |
| Safety | ||||
| Net Debt / EBITDA | 0.15 | 0.18 | 0.34 | 0.31 |
| Interest Coverage | -1,050.74 | -844.54 | -916.23 | -574.46 |
| Efficiency | ||||
| Inventory Turnover | 0.00 | 0.00 | -0.24 | -0.27 |
| Cash Conversion Cycle | 7.34 | 87.14 | -2,013.66 | -1,978.12 |